Doug Drysdale, CEO of Cybin, Inc. - a podcast by MJToday Media

Doug Drysdale, CEO of Cybin Inc., a leading biotechnology company focused on progressing psychedelic therapeutics to treat psychiatric disorders utilizing proprietary drug discovery platforms, innovative delivery systems, and novel formulations and treatment regiments, is this week’s special guest on the Green Rush!







Our hosts Anne and Nick sat down with Doug to talk about all things Cybin including the Company’s recent listing on the NEO exchange, its partnerships with Catalent and Kernel, its expanding IP portfolio as well as its growth and expansion plans for 2021 and beyond. In addition, we look at the future of regulations for the psychedelic space, when clinical data may become available and the similarities and differences between psychedelics and cannabis for investors.  







Cybin is one of the most exciting companies in the nascent psychedelics space and it was a real treat to chat with Doug and get an in-depth look at how the company is differentiating itself from its competitors.







Don’t sit back, lean forward and enjoy!















Doug Drysdale, CEO of Cybin, Inc. 







Doug Drysldale has chaired the Board of a NASDAQ-listed company and, as CEO for the past 12 years, has built and turned-around 3 pharmaceutical companies. During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 15 corporate acquisitions across three continents and has raised $4 billion of both public and private capital. Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the United Kingdom and was recognized as Entrepreneur of the Year by Ernst and Young in 2012. 







Links and mentions in the show







Cybin website: https://www.cybin.com/ Cybin X Kernel: https://www.cybin.com/kernel Cybin X Catalent: https://www.catalent.com/catalent-news/catalent-signs-drug-development-agreement-with-cybin-inc-for-its-fast-dissolve-formulation-of-novel-deuterated-tryptamine-cyb003/ 







Links to the guest’s company and social media accounts







Cybin’s Twitter: https://twitter.com/CybinInc Cybin’s Instagram: https://www.instagram.com/cybininc/ Cybin’s LinkedIn: https://www.linkedin.com/company/cybin/ Doug’s LinkedIn: https://www.linkedin.com/in/dougdrysdale/ 







Show Credits:







This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.







Special thanks to our Program Director Shea Gunther.







You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:







Twitter: @The_GreenRush 







Instagram: @thegreenrush_podcast







LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/ 







Facebook: https://www.facebook.com/TheGreenRushPodcast/ 







YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

Further episodes of 301 Moved Permanently

Further podcasts by MJToday Media

Website of MJToday Media